2FIRSTS | 2Firsts Compliance Solutions Hosts PMTA Briefing on FDA Review Signals After JUUL2 Authorization
2Firsts hosted a briefing analyzing FDA's JUUL2 authorization and its signals for PMTA review standards and market access.Summary
Following FDA's August 28, 2026 authorization of JUUL2 and recent ZYN ULTRA pouches, 2Firsts Compliance Solutions held a September 4 briefing for industry participants. The session analyzed what these Marketing Granted Orders (MGOs) indicate about the FDA's PMTA process. Key insights included: FDA reviews remain rigorous with multiple information requests, despite efforts to reduce backlog; "complete switching" from combustibles is a critical evaluation factor; and MGOs are part of a complex market-access system involving federal, state, and commercial layers. Experts advised brands, manufacturers, and investors to reassess U.S. market exposure, emphasizing compliance, documentation, and long-term strategy amid evolving regulations and ongoing litigation, such as the Altria-led lawsuit challenging FDA's PMTA rule.
(Source：2Firsts)
